Legal Update
In Federal case number 2:11-cv-02797, Dr. Aoki and ADRI vs Gregory Ford Gilbert, Trina Health, Bionica, Inc, et al, a Stipulation, Consent Judgment and Permanent Injunction was granted in favor of the Plaintiffs as to certain named Defendants involved with a clinic that had been located in Hayward, … Continue reading →
Legal Update
Dr. Aoki and ADRI continue to vigorously pursue the patent infringement action filed in 2011 against Gregory Ford Gilbert, Trina Health, Bionica Inc, and many others supposedly licensed by Mr. Gilbert and or his companies – US District Court, Eastern District of California, case … Continue reading →
Ongoing Lawsuit
One year ago, on Oct 24, 2011, ADRI and Dr. Aoki filed suit in Federal Court in Sacramento against Gregory Ford Gilbert and several companies and individuals associated with Mr. Gilbert. The suit seeks relief for nine causes of action, … Continue reading →
ADRI Celebrates 25 Years
A dinner honoring current and former ADRI staff and friends was held September 11th at Chinois City Cafe in Sacramento. … Continue reading →
Medicare National Payment Decision
In December of last year, the Centers for Medicare and Medicaid Services (CMS) published their Final Decision regarding outpatient intravenous insulin therapy. They decided there was not sufficient evidence that the therapy improves health outcomes in Medicare beneficiaries and they made … Continue reading →
Proposed Decision Regarding National Coverage Analysis of MAT® Treatment
In August, Dr. Aoki was delighted to personally present information about the scientific aspects of MAT® treatment, its history and long term safety record to a meeting of CMS and FDA staff. In mid-September, the Center for Medicare and Medicaid Services (CMS) published theirProposed … Continue reading →
National Coverage Analysis of Outpatient Intravenous Insulin Therapy
Medicare often makes National Coverage Determinations which set forth the extent to which Medicare will cover specific services, procedures, or technologies on a national basis. Medicare has begun making such a determination for MAT®Treatment (Metabolic Activation Therapy), under the broader class of therapies … Continue reading →